Theralase Technologies Inc. announced that it has filed a US patent, titled "Enhanced Immunotherapeutic Method Comprising Combined Administration of Photodynamic /Radiotherapeutic Compounds and Immunotherapeutic Agents" for enhanced destruction of cancer. The patent submission details combining Theralase®?'s patented PDC technology with immunotherapy drugs for increased cancer kill and continues to build on Theralase®?''s burgeoning intellectual property portfolio governing its PDCs, how they target cancer cells and how to best activate them safely and effectively to destroy cancer cells, while leaving healthy cells intact. Over the last decade, immunotherapy drugs have delivered stellar results for some cancer patients; but, unfortunately zero benefit for others, with only 20 to 40% of patients deriving benefit, based primarily on the type of antigen that presents on an individual patient's cancer cells and the relatively low percentage Based on the mechanism of action of Theralase®?''s PDCs, strong safety profile and strong efficacy, as a single anti-cancer agent in registered clinical study and the benefits of Rutherrin®?, as an intravenous administered drug, particularly in combination with radiotherapy, in preclinical research, it strongly supports achieving even higher tumour destruction and a complete response in patients by combining Theralase®?

PDCs with immunotherapy for various cancers.